{"id":"W2764109025","doi":"10.1111/bjd.16050","title":"Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)","year":2017,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":94,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Etanercept; Medicine; Placebo; Psoriasis; Psoriasis Area and Severity Index; Internal medicine; Post-hoc analysis; Dosing; Dermatology; Secukinumab; Tumor necrosis factor alpha; Psoriatic arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.02940632,0.001984084,0.006850626,0.002580078,0.000583509,0.002796446,0.0009256596,0.001593094,0.002563279],"category_scores_gemma":[0.01993906,0.0008749807,0.01393526,0.002510409,0.001034412,0.001180076,0.001285868,0.001438438,0.000212624],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001208725,"about_ca_system_score_gemma":0.002042694,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007478555,"about_ca_topic_score_gemma":0.001753939,"domain_scores_codex":[0.978779,0.01306154,0.002731884,0.001778398,0.002970793,0.0006783664],"domain_scores_gemma":[0.977783,0.008976183,0.008350541,0.001917369,0.001870523,0.00110229],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.7182478,0.002537148,0.02145378,0.01250019,0.1829815,0.00009882661,0.0002126913,0.001125098,0.006613729,0.0001645407,0.0008406264,0.05322412],"study_design_scores_gemma":[0.5349181,0.09546944,0.116608,0.001419746,0.2406488,0.0003407191,0.0001572601,0.001896547,0.003391978,0.0004185385,0.004536737,0.0001940772],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.827727,0.1333985,0.009722722,0.0004953287,0.0004079249,0.01667575,0.00822465,0.0004471882,0.002900968],"genre_scores_gemma":[0.9661188,0.01534932,0.006527868,0.0005484627,0.0002844606,0.006520467,0.004003917,0.00007610892,0.0005706673],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9931494,"threshold_uncertainty_score":0.1555173,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0660134355339033,"score_gpt":0.3257095382569747,"score_spread":0.2596961027230714,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}